Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q4 2022 Earnings Call Transcript

Unidentified Analyst: All right. Thank you for that. And then just back to the PX quickly. I guess any incremental color or updates I mean you can give on key milestones or kind of like the time line of what we should be looking out for updates regarding that? Thank you.

Drew Spaventa: Yes. So like we answered the question with Dan, we’ve signed our first technology access partner. We plan to do one or two more of those this year and to kind of have different types of experiments demonstrated with each. We still don’t have a product release date, it will take additional resources to develop that product, and we are still really focused on the G4. We have additional kits coming out in the G4 later this year. We have upgrades throughout the year planned. So I think at this point, we don’t have much more color. We are building a large fleet of betas. We’ve talked about that. We should have close to a dozen betas by the end of this year up and running. So we really have throughput to evaluate external samples, potentially place the beta next year or two if we want to.

So I think we will probably have more color on that towards the second half of this year as we kind of get the G4 scaled and successful in market and start to shift a little bit to product development and timing for the PX.

Unidentified Analyst: Okay. That’s helpful. Thank you.

Operator: Thank you. As there are no further questions in queue, this does conclude today’s conference call. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation.